Popular on eTradeWire


Similar on eTradeWire

Human Recombinant Neutrophil Gelatinase-associated Lipocalin (NGAL)

eTradeWire News/10768888
SAN DIEGO - eTradeWire -- Human Recombinant Neutrophil Gelatinase-associated Lipocalin (NGAL)

Catalog Number: B2016474 (50 ug)
Human Recombinant Neutrophil Gelatinase-associated Lipocalin (NGAL) is a high quality synthetic DNA fragment encoding amino acids 21-198 of human NGAL (Accession number UniProtKB P80188, NGAL_HUMAN). This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request.

Human Recombinant Neutrophil Gelatinase-associated Lipocalin (NGAL)
Catalog number:
B2016474
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 50 ug
Molecular Weight or Concentration: 21 515 Da
Supplied as: Powder
Applications: a molecular tool for various biochemical applications
Storage: -20 °C

More on eTradeWire News
Keywords: Neutrophil gelatinase-associated lipocalin (NGAL), human, recombinant
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Bolignano D, Coppolino G, Donato V, Lacquaniti A, Bono C, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle? Med Sci Monit. 2010 Jun;16(6):RA131-5.
2: Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Gröger M, Klinger M, Wojta J, Neumayer C, Huk I, Demyanets S. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In Vitro Eur J Vasc Endovasc Surg. 2016 May;51(5):623-31.

https://moleculardepot.com/product/human-recombinant-neutrophil-gelatinase-associated-lipocalin-ngal/

Contact
Molecular Depot
info@molecular-depot.com
(858)900-3210


Source: Molecular Depot
Filed Under: Biotech

Show All News | Report Violation

0 Comments